ReviewImmune network2018
Role of IL-32 Gamma on Bone Metabolism in Autoimmune Arthritis.
Review in Immune network, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 18 citations in OpenAlex.
- Can Blood Cell Count-Based Inflammatory Markers Reflect the Risk of Osteoporosis? A Cross-Sectional and Genetic Analysis.Immunity, inflammation and disease · 2026Article
- Article
- Article
- A1AT dysregulation of metabolically stressed hepatocytes by Kupffer cells drives MASH and fibrosis.Experimental & molecular medicine · 2025Article
- Association Between Serum Interleukin-32 Level and Disease Status in Cases with Neuromyelitis Optica Spectrum Disorders.Journal of inflammation research · 2024Article
- Association between inflammatory markers and bone mineral density: a cross-sectional study from NHANES 2007-2010.Journal of orthopaedic surgery and research · 2023Article
- Interleukin-32 as a biomarker in rheumatic diseases: A narrative review.Frontiers in immunology · 2023Review
- Microarchitecture of historic bone samples with tuberculosis.Wiener klinische Wochenschrift · 2022Article
- Targeting TIGIT Inhibits Bladder Cancer Metastasis Through Suppressing IL-32.Frontiers in pharmacology · 2021Article
- Inhibition of IL-32 Expression Ameliorates Cerebral Ischemia-Reperfusion Injury via the NOD/MAPK/NF-κB Signaling Pathway.Journal of molecular neuroscience : MN · 2020Article
- A correlative studies between osteoporosis and blood cell composition: Implications for auxiliary diagnosis of osteoporosis.Medicine · 2020Article
- Expression of interleukin-32 in bone marrow of patients with myeloma and its prognostic significance.World journal of clinical cases · 2019Article
- Structural Characteristics of Seven IL-32 Variants.Immune network · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
IL-32 acts as a pro-inflammatory cytokine by inducing the synthesis of inflammatory molecules as well as promoting the morphological changes involved in the transformation of monocytes into osteoclasts (OCs). Evaluation of the functions of IL-32 has mainly focused on its inflammatory properties, such as involvement in the pathogenesis of various autoimmune diseases. Recently, IL-32 was shown to be involved in bone metabolism, in which it promotes the differentiation and activation of OCs and plays a key role in bone resorption in inflammatory conditions. IL-32γ also regulates bone formation in conditions such as ankylosing spondylitis and osteoporosis. In this review, we summarize the results of recent studies on the role of IL-32γ in bone metabolism in inflammatory arthritis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.